Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.
A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects
Sponsor: Janssen Sciences Ireland UC
Listed as NCT02387606, this PHASE2 trial focuses on Respiratory Syncytial Virus Infections and remains completed. Sponsored by Janssen Sciences Ireland UC, it has been updated 10 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Nov 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Sciences Ireland UC
For direct contact, visit the study record on ClinicalTrials.gov .